ReNeuron Group plc
("ReNeuron" or "the Company" or "the Group")
Grant of Options
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that grants were made on 14 February 2023 for options over 4,030,000 Ordinary Shares of 1p each ("Options") under the terms of the Company's Long Term Incentive Plan ("The Plan") and its Non-Executive Share Option Scheme. The grants of 3,000,000 Options made to Directors and Persons Discharging Managerial Responsibilities (PDMRs) are set out further in the table below.
1,615,000 of the Options granted under The Plan have an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days.
The remaining 1,415,000 of the Options granted under The Plan have an exercise price of 31.5 pence per share. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. None of these Options are subject to any further performance conditions.
The 1,000,000 Options granted to Iain Ross are granted under the Non-Executive Share Option Scheme. 750,000 of the Options are granted with an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days. 250,000 of the Options are granted with an exercise price of 50.0 pence per share without any further performance conditions. All of Mr Ross's options vest monthly over three years on a straight-line basis.
|
Name |
Title |
Date of grant of Options |
Number of Options granted
|
Total shares over which options are held (post award) |
Percentage of issued shares under option |
|
Iain Ross |
Executive Chairman |
14 February 2023 |
1,000,000 |
1,500,000 |
2.62% |
|
John Hawkins |
Chief Financial Officer |
14 February 2023 |
500,000 |
840,000 |
1.47% |
|
Randolph Corteling |
Chief Scientific Officer |
14 February 2023 |
500,000 |
1,000,000 |
1.75% |
|
Simon Dew |
Chief Business Officer |
14 February 2023 |
600,000 |
600,000 |
1.05% |
|
Suzanne Hancock |
Chief Operations Officer |
14 February 2023 |
400,000 |
749,326 |
1.31% |
ENDS
Enquiries:
|
ReNeuron |
||
|
Iain Ross, Chairman |
Via Walbrook PR |
|
|
John Hawkins, Chief Financial Officer |
|
|
|
|
|
|
|
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) |
+44 (0)20 3100 2000
|
|
|
|
|
|
|
Allenby Capital Limited (Joint Broker) |
+44 (0)20 3328 5656 |
|
|
James Reeve/George Payne (Corporate Finance) |
|
|
|
Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to grant of share options to Directors and PDMRs)
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Name |
Iain Ross |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Executive Chairman |
||||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
ReNeuron Group plc |
||||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||||
|
b) |
Nature of the transaction |
Grant of share options |
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information |
N/A |
||||||
|
e) |
Date of the transaction |
14 February 2023 |
||||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Name |
John Hawkins |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Financial Officer |
||||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
ReNeuron Group plc |
||||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||||
|
b) |
Nature of the transaction |
Grant of share options |
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information |
N/A |
||||||
|
e) |
Date of the transaction |
14 February 2023 |
||||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Name |
Randolph Corteling |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Scientific Officer |
||||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
ReNeuron Group plc |
||||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||||
|
b) |
Nature of the transaction |
Grant of share options |
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information |
N/A |
||||||
|
e) |
Date of the transaction |
14 February 2023 |
||||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Name |
Simon Dew |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Chief Business Officer |
||||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
ReNeuron Group plc |
||||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||||
|
b) |
Nature of the transaction |
Grant of share options |
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information |
N/A |
||||||
|
e) |
Date of the transaction |
14 February 2023 |
||||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||
|
a) |
Name |
Suzanne Hancock |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Head of Operations |
||||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
ReNeuron Group plc |
||||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||||
|
b) |
Nature of the transaction |
Grant of share options |
||||||
|
c) |
Price(s) and volume(s)
|
|
||||||
|
d)
|
Aggregated information |
N/A |
||||||
|
e) |
Date of the transaction |
14 February 2023 |
||||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
